Data Driven Toxicity Management For Adcs

Summary

Terence Friedlander, MD, University of California, San Francisco, CA, highlights key factors physicians must consider when ... Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, discusses Melissa Calopiz, University of Michigan, Ann Arbor, MI, reviews the different ways to optimize antibody-drug conjugate ( Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Korea, discusses the use of antibody-drug conjugates in breast cancer, ... Angeles Secord, MD, Duke Cancer Institute, Durham, NC, emphasizes the importance of a multidisciplinary approach in ... In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates ( As antibody-drug conjugates become increasingly integrated across oncology, Predictive bioanalytical strategies for the development of Antibody-Drug Conjugates ( Amy Johnson, Ph.D., VP of Medical Affairs at Vincerx, Sandra Poole, Chief Operating Officer at Mythic Therapeutics, and DeciBio ... Drs. Mariam Haji ahmad(Roswell Park) and Alexis Levee (UCLA) tackle one of the most pressing questions in breast oncology: ... The frontline landscape for metastatic TNBC now includes multiple Presentation led by Marco Lobba, PhD at Antibody Engineering & Therapeutics USA.